MPLT (MapLight Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by MPLT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | James Woodruff Lillie | Chief Scientific Officer | A | — | — |
| 2026-08-19 | Kristopher Hanson | General Counsel | A | — | — |
| 2026-08-19 | Erin Pennock Foff | Chief Medical Officer | A | — | — |
| 2026-08-19 | Anatol Kreitzer | Chief Discovery Officer | A | — | — |
| 2026-08-19 | Christopher A. Kroeger | Chief Executive Officer | A | — | — |
| 2026-08-19 | JONATHAN GILLIS | CAO and Interim CFO | A | — | — |
| 2026-08-18 | Catalyst4, Inc. | 10%+ Owner | Buy | — | — |
| 2026-08-04 | James Woodruff Lillie | Chief Scientific Officer | Sell | — | — |
| 2026-07-30 | Catalyst4, Inc. | 10%+ Owner | Buy | — | — |
| 2026-07-28 | Troy Cox | Director | Buy | — | — |
| 2026-07-20 | Anatol Kreitzer | Chief Discovery Officer | Sell | — | — |
| 2026-07-20 | JONATHAN GILLIS | CAO and Interim CFO | Sell | — | — |
| 2026-07-17 | Kristopher Hanson | General Counsel | Sell | — | — |
| 2026-07-17 | James Woodruff Lillie | Chief Scientific Officer | Sell | — | — |
| 2026-07-17 | Erin Pennock Foff | Chief Medical Officer | Sell | — | — |
| 2026-07-17 | Christopher A. Kroeger | Chief Executive Officer | Sell | — | — |
| 2026-06-25 | Maria C Walker | Director | A | — | — |
| 2026-06-25 | George Pavlov | Director | A | — | — |
| 2026-06-25 | Martin Babler | Director | A | — | — |
| 2026-06-25 | Timothy John Garnett | Director | A | — | — |
| 2026-06-25 | Troy Cox | Director | A | — | — |
| 2026-06-25 | Nanna Liebach Luneborg | Director | A | — | — |
| 2026-05-18 | Christopher A. Kroeger | Chief Executive Officer | Sell | — | — |
| 2026-05-11 | Erin Pennock Foff | Chief Medical Officer | Sell | — | — |
| 2026-05-11 | James Woodruff Lillie | Chief Scientific Officer | Sell | — | — |
| 2026-05-11 | Christopher A. Kroeger | Chief Executive Officer | Sell | — | — |
| 2026-05-11 | Kristopher Hanson | General Counsel | Sell | — | — |
| 2026-05-06 | James Woodruff Lillie | Chief Scientific Officer | Sell | — | — |
| 2026-05-06 | Christopher A. Kroeger | Chief Executive Officer | Sell | — | — |
| 2026-05-06 | Kristopher Hanson | General Counsel | Sell | — | — |
| 2026-05-06 | Vishwas Setia | Chief Financial Officer | Sell | — | — |
| 2026-05-06 | Erin Pennock Foff | Chief Medical Officer | Sell | — | — |
| 2026-04-29 | Anatol Kreitzer | Chief Discovery Officer | Sell | — | — |
| 2026-04-29 | JONATHAN GILLIS | CAAO and PAO | Sell | — | — |
| 2026-04-17 | JONATHAN GILLIS | CAAO and PAO | Sell | — | — |
| 2026-04-17 | Anatol Kreitzer | Chief Discovery Officer | Sell | — | — |
| 2026-04-17 | Robert C. Malenka | Director | Sell | — | — |
| 2026-04-17 | Christopher A. Kroeger | Chief Executive Officer | Sell | — | — |
| 2026-04-17 | Erin Pennock Foff | Chief Medical Officer | Sell | — | — |
| 2026-04-17 | James Woodruff Lillie | Chief Scientific Officer | Sell | — | — |
| 2026-04-17 | Vishwas Setia | Chief Financial Officer | Sell | — | — |
| 2026-04-17 | Kristopher Hanson | General Counsel | Sell | — | — |
| 2026-02-24 | Robert C. Malenka | Director | Sell | — | — |
| 2026-02-20 | George Pavlov | Director | Buy | — | — |
| 2026-02-18 | Robert C. Malenka | Director | Sell | — | — |
| 2026-02-12 | Robert C. Malenka | Director | Sell | — | — |
| 2026-02-12 | Timothy John Garnett | Director | Buy | — | — |
| 2026-02-09 | James Woodruff Lillie | Chief Scientific Officer | A | — | — |
| 2026-02-09 | Vishwas Setia | Chief Financial Officer | A | — | — |
| 2026-02-09 | Anatol Kreitzer | Chief Discovery Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 25,306,689 | — |
| — | 10%+ Owner | 2,733,681 | — |
| — | Chief Executive Officer | 1,370,790 | — |
| — | Chief Financial Officer | 378,510 | — |
| — | Director | 348,138 | — |
| — | Chief Medical Officer | 312,261 | — |
| — | Chief Scientific Officer | 210,110 | — |
| — | Chief Discovery Officer | 180,926 | — |
| — | General Counsel | 153,553 | — |
| — | CAO and Interim CFO | 152,482 | — |
| — | Director | 67,581 | — |
| — | Director | 62,703 | — |
| — | Director | 28,932 | — |
| — | Director | 23,484 | — |
| — | Director | 7,864 | — |
| — | Director | 3,932 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MPLT quote page; the site-wide leaderboard is on the insider transactions hub.